Overview
Preoxygenation With Optiflow™ in Morbidly Obese Patients is Superior to Face Mask
Status:
Withdrawn
Withdrawn
Trial end date:
2019-12-01
2019-12-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Optiflow™ may provide an opportunity to prolong apnea time in the morbidly obese patient population. This study will examine whether Optiflow can do this, and compare the pre-oxygenation with Optiflow to the pre-oxygenation achieved with face mask.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Montefiore Medical CenterCollaborators:
M.D. Anderson Cancer CenterThe University of Texas Health Science Center, Houston
Treatments:
FentanylMidazolam
Propofol
Rocuronium
Criteria
Inclusion Criteria:- Adult patients (≥ 18 years old) undergoing elective surgery requiring general
anesthesia
- BMI > 40 kg/m2
- American Society of Anesthesiology (ASA) Physical Status II-III
Exclusion Criteria:
- Chronic hypoxemia (SpO2 <94% on room air or on home oxygen)
- Acute respiratory failure
- Coronary artery disease and/or congestive heart failure
- Moderate-Severe pulmonary hypertension and/or RV dysfunction
- Full stomach (recently eaten)
- Pregnancy
- Chronic pulmonary disease (specifically COPD or interstitial disease, NOT asthma)
- Respiratory tract pathology
- Facial Abnormality
- American Society of Anesthesiology (ASA) Physical Status IV-V